HCM
Price
$16.22
Change
+$0.13 (+0.81%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
2.8B
39 days until earnings call
TLRY
Price
$1.58
Change
-$0.04 (-2.47%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
1.8B
3 days until earnings call
Interact to see
Advertisement

HCM vs TLRY

Header iconHCM vs TLRY Comparison
Open Charts HCM vs TLRYBanner chart's image
HUTCHMED (China)
Price$16.22
Change+$0.13 (+0.81%)
Volume$422
Capitalization2.8B
Tilray Brands
Price$1.58
Change-$0.04 (-2.47%)
Volume$131.2K
Capitalization1.8B
HCM vs TLRY Comparison Chart in %
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HCM vs. TLRY commentary
Oct 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HCM is a Hold and TLRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 06, 2025
Stock price -- (HCM: $16.09 vs. TLRY: $1.62)
Brand notoriety: HCM: Not notable vs. TLRY: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HCM: 123% vs. TLRY: 111%
Market capitalization -- HCM: $2.8B vs. TLRY: $1.8B
HCM [@Pharmaceuticals: Generic] is valued at $2.8B. TLRY’s [@Pharmaceuticals: Generic] market capitalization is $1.8B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.89B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HCM’s FA Score shows that 1 FA rating(s) are green whileTLRY’s FA Score has 0 green FA rating(s).

  • HCM’s FA Score: 1 green, 4 red.
  • TLRY’s FA Score: 0 green, 5 red.
According to our system of comparison, both HCM and TLRY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HCM’s TA Score shows that 2 TA indicator(s) are bullish while TLRY’s TA Score has 5 bullish TA indicator(s).

  • HCM’s TA Score: 2 bullish, 7 bearish.
  • TLRY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, TLRY is a better buy in the short-term than HCM.

Price Growth

HCM (@Pharmaceuticals: Generic) experienced а +2.88% price change this week, while TLRY (@Pharmaceuticals: Generic) price change was +40.87% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.37%. For the same industry, the average monthly price growth was +5.95%, and the average quarterly price growth was +58.35%.

Reported Earning Dates

HCM is expected to report earnings on Nov 14, 2025.

TLRY is expected to report earnings on Oct 09, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.37% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HCM($2.8B) has a higher market cap than TLRY($1.8B). TLRY YTD gains are higher at: 21.805 vs. HCM (11.659). HCM has higher annual earnings (EBITDA): 38M vs. TLRY (-2.13B). HCM has more cash in the bank: 1.37B vs. TLRY (256M). HCM has less debt than TLRY: HCM (93.4M) vs TLRY (329M). TLRY has higher revenues than HCM: TLRY (821M) vs HCM (602M).
HCMTLRYHCM / TLRY
Capitalization2.8B1.8B156%
EBITDA38M-2.13B-2%
Gain YTD11.65921.80553%
P/E Ratio6.08N/A-
Revenue602M821M73%
Total Cash1.37B256M533%
Total Debt93.4M329M28%
FUNDAMENTALS RATINGS
HCM vs TLRY: Fundamental Ratings
HCM
TLRY
OUTLOOK RATING
1..100
7279
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1998
PRICE GROWTH RATING
1..100
5535
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
5036

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TLRY's Valuation (51) in the Biotechnology industry is somewhat better than the same rating for HCM (89) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew somewhat faster than HCM’s over the last 12 months.

TLRY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HCM (100) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to HCM’s over the last 12 months.

HCM's SMR Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for TLRY (98) in the Biotechnology industry. This means that HCM’s stock grew significantly faster than TLRY’s over the last 12 months.

TLRY's Price Growth Rating (35) in the Biotechnology industry is in the same range as HCM (55) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to HCM’s over the last 12 months.

TLRY's P/E Growth Rating (95) in the Biotechnology industry is in the same range as HCM (100) in the Pharmaceuticals Major industry. This means that TLRY’s stock grew similarly to HCM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HCMTLRY
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
75%
Bullish Trend 4 days ago
80%
MACD
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 5 days ago
74%
Bullish Trend 13 days ago
83%
Declines
ODDS (%)
Bearish Trend 11 days ago
80%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
HCM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
APDQX15.680.10
+0.64%
Artisan Mid Cap Value Advisor
DRLIX8.830.03
+0.34%
BNY Mellon Developed Markets RE Scs - I
CGVBX27.750.09
+0.33%
American Funds Global Insight 529-C
TEQIX15.910.05
+0.32%
Franklin Mutual Quest A
RSMOX24.57-0.08
-0.32%
Victory RS Mid Cap Growth A

HCM and

Correlation & Price change

A.I.dvisor tells us that HCM and ACET have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HCM and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HCM
1D Price
Change %
HCM100%
-0.19%
ACET - HCM
29%
Poorly correlated
+0.80%
TLRY - HCM
27%
Poorly correlated
+0.62%
CGC - HCM
27%
Poorly correlated
+0.74%
SNDL - HCM
25%
Poorly correlated
+1.98%
IRWD - HCM
24%
Poorly correlated
-3.73%
More

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
+0.62%
SNDL - TLRY
76%
Closely correlated
+1.98%
CRON - TLRY
64%
Loosely correlated
-0.39%
OGI - TLRY
64%
Loosely correlated
+0.53%
CGC - TLRY
62%
Loosely correlated
+0.74%
ACB - TLRY
61%
Loosely correlated
-0.53%
More